Literature DB >> 33845778

Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.

Maurício Fregonesi Barbosa1,2, Daniéliso Renato Fusco3, Rafael Dezen Gaiolla4, Konrad Werys5, Suzana Erico Tanni6, Rômulo Araújo Fernandes7, Sergio Marrone Ribeiro8, Gilberto Szarf9,10.   

Abstract

BACKGROUND: The use of anthracycline-based chemotherapy is associated with the development of heart failure, even years after the end of treatment. Early detection of cardiac dysfunction could identify a high-risk subset of survivors who would eventually benefit from early intervention. Cardiac magnetic resonance feature-tracking (CMR-FT) analysis offers a practical and rapid method to calculate systolic and diastolic strains from routinely acquired cine images. While early changes in systolic function have been described, less data are available about late effects of chemotherapy in diastolic parameters by CMR-FT. The main goal of this study was to determine whether left ventricular (LV) early diastolic strain rates (GDSR-E) by CMR-FT are impaired in long-term adult survivors of non-Hodgkin lymphoma (NHL). Our secondary objective was to analyze associations between GDSR-E with cumulative anthracycline dose, systolic function parameters and myocardial tissue characteristics.
METHODS: This is a single center cross-sectional observational study of asymptomatic patients in remission of NHL who previously received anthracycline therapy. All participants underwent their CMR examination on a 3.0-T scanner, including cines, T2 mapping, T1 mapping and late gadolinium enhancement imaging. Derived myocardial extracellular volume fraction was obtained from pre- and post-contrast T1 maps. CMR-FT analysis was performed using Trufi Strain software. The data obtained were compared between anthracycline group and volunteers without cardiovascular disease or neoplasia.
RESULTS: A total of 18 adult survivors of NHL, 14 (77.8%) males, at mean age of 57.6 (± 14.7) years-old, were studied 88.2 (± 52.1) months after exposure to anthracycline therapy (median 400 mg/m2). Compared with controls, anthracycline group showed impaired LV global early diastolic circumferential strain rate (GCSR-E) [53.5%/s ± 19.3 vs 72.2%/s ± 26.7, p = 0.022], early diastolic longitudinal strain rate (GLSR-E) [40.4%/s ± 13.0 vs 55.9%/s ± 17.8, p = 0.006] and early diastolic radial strain rate (GRSR-E) [- 114.4%/s ± 37.1 vs - 170.5%/s ± 48.0, p < 0.001]. Impaired LV GCSR-E, GLSR-E and GRSR-E correlated with increased anthracycline dose and decreased systolic function. There were no correlations between GDSR-E and myocardial tissue characteristics.
CONCLUSIONS: Left ventricular early diastolic strain rates by CMR-FT are impaired late after anthracycline chemotherapy in adult survivors of non-Hodgkin lymphoma.

Entities:  

Keywords:  Cancer; Chemotherapy; Diastolic dysfunction; Feature-tracking; Strain

Year:  2021        PMID: 33845778     DOI: 10.1186/s12872-021-01996-6

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  46 in total

1.  Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?

Authors:  Michael S Ewer; Daniel J Lenihan
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

3.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

4.  Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.

Authors:  Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Saskia le Cessie; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine van Glabbeke; Hanneke C Kluin-Nelemans
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

5.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Gaia De Giacomi; Mara Rubino; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  J Am Coll Cardiol       Date:  2010-01-19       Impact factor: 24.094

6.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Am J Cardiol       Date:  2011-03-02       Impact factor: 2.778

7.  Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.

Authors:  András Csaba Nagy; Zsuzsanna Cserép; Edina Tolnay; Tamás Nagykálnai; Tamás Forster
Journal:  Pathol Oncol Res       Date:  2008-03-15       Impact factor: 3.201

8.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

Authors:  O Hequet; Q H Le; I Moullet; E Pauli; G Salles; D Espinouse; C Dumontet; C Thieblemont; P Arnaud; D Antal; F Bouafia; B Coiffier
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

9.  Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Authors:  Brandon C Drafts; Katie M Twomley; Ralph D'Agostino; Julia Lawrence; Nancy Avis; Leslie R Ellis; Vinay Thohan; Jennifer Jordan; Susan A Melin; Frank M Torti; William C Little; Craig A Hamilton; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2013-05-01

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983

View more
  1 in total

Review 1.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.